Is Lurbinectedin Approved for Oral Use?
No, lurbinectedin (brand name Zepzelca) is administered only intravenously (IV), not orally. It is a prescription chemotherapy drug infused over 60 minutes every 21 days.[1]
Why No Oral Formulation?
Lurbinectedin is a marine-derived alkaloid that requires IV delivery for proper absorption and bioavailability. Oral administration is not feasible due to its chemical properties and pharmacokinetics, which are optimized for IV use in clinical settings.[1][2]
Use in Infants or Pediatrics?
Lurbinectedin is FDA-approved only for adults with metastatic small cell lung cancer after platinum-based therapy. It has no approval, dosing guidelines, or safety data for infants or children. Pediatric trials are absent, and its use in patients under 18 is not studied or recommended.[1][3]
What Happens If Given Orally or to Infants?
Oral intake would likely result in negligible absorption, reducing efficacy and increasing risks like gastrointestinal toxicity without therapeutic benefit. In infants, IV use could cause severe, unstudied toxicities including bone marrow suppression, hepatotoxicity, and rhabdomyolysis—effects already common in adults. Off-label use in pediatrics is contraindicated due to lack of evidence.[2][3]
Alternatives for Pediatric Cancer Treatment?
For infant cancers like neuroblastoma or small cell equivalents, treatments include IV chemotherapies (e.g., cyclophosphamide, topotecan) or targeted agents, not lurbinectedin. Consult pediatric oncologists for age-appropriate options.[3]
[1]: FDA Label for Zepzelca (lurbinectedin)
[2]: Drugs.com - Lurbinectedin
[3]: Medscape - Lurbinectedin Dosing